PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.2106

Related search